BFRI

NASD Biofrontera, Inc.
Oct 5, 2026 · 9:53 PM ET EOD Market Closed

$0.8909 ↑ +0.0000 (+0.00%) Trading Up from the previous close of $0.8909, $0.1091 below the day’s high of $1.0000

YTD change
+56.30%
vs 20-day SMA
-29.45%
vs 200-day SMA
-12.89%

Price ranges

Previous day
$1.00 $1.12
open $1.05 close $1.02
-$0.04 (-3.33%)
Today
$0.8800 $1.0000
open $1.0000 now $0.8909
-$0.1091 (-10.91%)
Past week
$1.0000 $1.1800
from $1.1800 now $0.8909
-$0.2891 (-24.50%)
Past month
$1.0000 $1.6600
from $1.5100 now $0.8909
-$0.6191 (-41.00%)
This year
$0.5700 $1.6600
from $0.5700 now $0.8909
+$0.3209 (+56.30%)

Price & Performance

-0.10 (-10.01%) / 6M

$0.7127$1.03$1.36$1.68Apr 6Jul 7Oct 5

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Poor
  • The stock is 99.7% away from all-time highs of $292.6000
  • BFRI is up 56% since the beginning of the year
  • BFRI is down 17% over the past 12 months
  • BFRI is down 41% over the past 1 month
  • 3% of all BFRI investors are betting against BFRI

BFRI reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -16.0%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable No
EPS $-0.05
Earnings momentum +77.3% Quarterly EPS growth
Quarterly change +77.3%

Valuation

P/E ratio N/A
Enterprise value $16.0M
Beta 0.28

Balance sheet & scale

IncomeN/A
Revenue$46.2M
Cash$4.7M
Debt$7.5K
Income / Debt N/A

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Manufacturing
Sub Sector Chemical Manufacturing
Market cap $13.2M

Biofrontera, Inc. is a biopharmaceutical company, which engages in the commercialization of pharmaceutical products. It specializes in the treatment of dermatological conditions, caused primarily by exposure to sunlight that results in sun damage to the skin. The company focuses on the treatment of actinic keratosis and markets a topical antibiotic for treatment of impetigo. Its products include Ameluz and Xepi, its two prescription drugs, and BF-RhodoLED, a lamp used with Ameluz, for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company was founded on March 3, 2015 and is headquartered in Woburn, MA.

Competitor comparison

TickerCompany PriceChange
LLY Eli Lilly and Company $1,143.12 +0.02%
JNJ Johnson & Johnson $252.93 -1.21%
ABBV AbbVie, Inc. $265.76 +1.12%
MRK Merck & Co., Inc. $139.54 -3.30%
RHHVF Roche Holding Ltd $427.89 -0.08%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.